The Experts below are selected from a list of 789 Experts worldwide ranked by ideXlab platform

Denisse Vázquez-gonzález - One of the best experts on this subject based on the ideXlab platform.

  • Tinea imbricata in the Americas.
    Current opinion in infectious diseases, 2011
    Co-Authors: Alexandro Bonifaz, Denisse Vázquez-gonzález
    Abstract:

    Purpose of review The aim is to provide an overview on tinea imbricata, or Tokelau, a Superficial Mycosis caused by Trichophyton concentricum, a strictly anthropophilic dermatophyte with a well-defined geographic distribution and predisposing factors that include genetic, racial and immunologic susceptibility patterns and a specific environment. Recent findings This review covers the most interesting aspects of the infrequent disease tinea imbricata, including the historical background, the epidemiologic aspects, highlighting the genetic and racial patterns of susceptibility to the acquisition of the disease, and the immunologic aspects that help to explain its clinical behavior. We also present a clinical description of the disease, the differential diagnosis and how currently some other emerging diseases such as syphilis in immunocompromised patients can mimic tinea imbricata. The therapeutic options are still griseofulvin and nowadays terbinafine, but the access to the treatments in the endemic zones and the changes in habits of the affected population make control and prevention of the disease difficult. Summary Tinea imbricata, or Tokelau, remains an infrequent Superficial Mycosis restricted to endemic zones in the South Pacific islands (Polynesia and Melanesia), South Asia and some specific areas of South America. Migration phenomena and global changes in the climate may modify the incidence and characteristics of the disease.

Basista Prasad Rijal - One of the best experts on this subject based on the ideXlab platform.

  • Clinicomycological Characterization of Superficial Mycoses from a Tertiary Care Hospital in Nepal
    Dermatology research and practice, 2016
    Co-Authors: Sundar Khadka, Jeevan B. Sherchand, Dinesh Binod Pokharel, Bharat Mani Pokhrel, Shyam Kumar Mishra, Subhash Dhital, Basista Prasad Rijal
    Abstract:

    Background. Superficial Mycosis is a common fungal infection worldwide, mainly caused by dermatophytes. However, the prevalence of species varies geographically. In addition, fungal treatment is best guided according to species isolated. This study was carried out to determine the clinical as well as mycological profile of Superficial mycoses in a tertiary care hospital, Nepal. Methods. This was a prospective case-control laboratory based study conducted over a period of six months from January to June 2014 at Tribhuvan University Teaching Hospital, Nepal. A total of 200 specimens were collected from the patients suspected of Superficial mycoses. The specimens were macroscopically as well as microscopically examined. The growth was observed up to 4 weeks. Results. Out of total 200 specimens from the patients suspected of Superficial mycoses, tinea corporis 50 (25%) was most common clinical types. KOH mount was positive in 89 (44.5%) and culture was positive in 111 (55.5%). Trichophyton mentagrophytes 44 (39.6%) was the most common isolate. Conclusions. The diagnostic yields of KOH mount and culture were found to be complementary to each other. Thus both the methods added with clinical findings are equally important to establish Superficial Mycosis.

Silvio Alencar Marques - One of the best experts on this subject based on the ideXlab platform.

Alexandro Bonifaz - One of the best experts on this subject based on the ideXlab platform.

  • Pityriasis Versicolor in Children and Adolescents: an Update
    Current Fungal Infection Reports, 2019
    Co-Authors: Karen Adilene Camargo-sánchez, Mirna Toledo-bahena, Carlos Mena-cedillos, Erika Ramirez-cortes, Sonia Toussaint-caire, Adriana Valencia-herrera, Marcela Salazar-garcía, Alexandro Bonifaz
    Abstract:

    Purpose of Review Pityriasis versicolor (PV) is a Superficial Mycosis that it can occur at any age, even in newborns. In this review, we will describe epidemiological data, mycological characteristics of yeast, pathogenesis and clinical characteristics of the disease, different diagnostic resources, and the current recommendations for treatment.

  • Tinea imbricata in the Americas.
    Current opinion in infectious diseases, 2011
    Co-Authors: Alexandro Bonifaz, Denisse Vázquez-gonzález
    Abstract:

    Purpose of review The aim is to provide an overview on tinea imbricata, or Tokelau, a Superficial Mycosis caused by Trichophyton concentricum, a strictly anthropophilic dermatophyte with a well-defined geographic distribution and predisposing factors that include genetic, racial and immunologic susceptibility patterns and a specific environment. Recent findings This review covers the most interesting aspects of the infrequent disease tinea imbricata, including the historical background, the epidemiologic aspects, highlighting the genetic and racial patterns of susceptibility to the acquisition of the disease, and the immunologic aspects that help to explain its clinical behavior. We also present a clinical description of the disease, the differential diagnosis and how currently some other emerging diseases such as syphilis in immunocompromised patients can mimic tinea imbricata. The therapeutic options are still griseofulvin and nowadays terbinafine, but the access to the treatments in the endemic zones and the changes in habits of the affected population make control and prevention of the disease difficult. Summary Tinea imbricata, or Tokelau, remains an infrequent Superficial Mycosis restricted to endemic zones in the South Pacific islands (Polynesia and Melanesia), South Asia and some specific areas of South America. Migration phenomena and global changes in the climate may modify the incidence and characteristics of the disease.

Kwang Hoon Lee - One of the best experts on this subject based on the ideXlab platform.

  • Study to compare the efficacy and safety of fluconazole cream with flutrimazole cream in the treatment of Superficial Mycosis: a multicentre, randomised, double-blind, phase III trial
    Mycoses, 2009
    Co-Authors: S. M. Yim, Yang Won Lee, H. W. Kim, J. Y. Lee, Nack In Kim, Young Chul Kye, Kyoung Chan Park, Jee-ho Choi, Kwang Hoon Lee
    Abstract:

    Fluconazole, which is a drug of the azole family, is safely used in systemic treatment of oral and intravenous injection, but it is difficult to use fluconazole as a topical application because of its large molecular weight and strong hydrophilic property. This study is a multicentre, double-blind, randomised, non-inferiority study to compare the antifungal effect and safety of fluconazole cream 0.5% and 1% with flutrimazole cream 1% in Superficial Mycosis. A total of 162 subjects selected to participate in this study were equally divided into three groups and assigned to be given fluconazole cream 0.5%, fluconazole cream 1%, and flutrimazole cream 1% in the ratio of 1 : 1. The primary index of drug efficacy was determined by complete mycological cure in which no fungus was detected on KOH smear test 4 weeks after application of fluconazole. The secondary index of efficacy was defined as complete mycological cure 4 weeks after the application of fluconazole, improvement of clinical symptoms and overall effectiveness assessed by the research staff. According to this study, on comparing the efficacy of cure of Superficial dermatoMycosis after 4 weeks of application, both fluconazole 0.5% and fluconazole 1% cream were found to be equally effective and non-inferior to flutrimazole 1% cream. Given the effectiveness and safety of the drug, both fluconazole 0.5% and 1% cream might be said to be optimal concentration in the treatment of Superficial dermatoMycosis.